B7-33 vs Omega-3 (EPA/DHA)
A side-by-side research comparison of B7-33 and Omega-3 (EPA/DHA) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | B7-33 | Omega-3 (EPA/DHA) |
|---|---|---|
| Full name | B7-33 (Relaxin Peptide Analog) | Omega-3 Fatty Acids (EPA + DHA) |
| Category | Cardiovascular | Cardiovascular |
| Status | Research peptide (preclinical) | Dietary supplement / FDA-approved (Rx fish oil) |
| Mechanism | Selectively activates the relaxin receptor RXFP1 pathway, biasing signaling toward anti-fibrotic effects. It reduces collagen deposition and promotes healthy tissue remodeling in heart, lung, and kidney models without some downsides of full-length relaxin. | EPA/DHA incorporate into cell membranes, displacing arachidonic acid and reducing pro-inflammatory eicosanoid production. Generate resolvins and protectins for active inflammation resolution. Activate PPARγ and inhibit NF-κB. |
| Molecular weight | ~3.3 kDa | EPA: 302.45 Da, DHA: 328.49 Da |
| Half-life | Short (peptide) | ~48-72 hours (membrane incorporation) |
| Bioavailability | Injection (research) | Triglyceride form: ~70%; ethyl ester: ~30-40%; phospholipid (krill): ~85% |
| Typical dose | Not established for humans | 2-4g combined EPA+DHA |
| Frequency | Research only | Daily with meals |
| Route | Injection (research) | Oral (softgel, liquid) |
B7-33 reported benefits
- Anti-fibrotic effects (preclinical)
- Cardiac and organ protection (research)
- Healthy tissue remodeling
- Relaxin-pathway (RXFP1) biased signaling
Omega-3 (EPA/DHA) reported benefits
- Triglyceride reduction (25-45%)
- Anti-inflammatory (SPM production)
- Cardiac rhythm stabilization
- Brain and cognitive support
- Joint inflammation reduction
- Membrane fluidity optimization
Related comparisons
Research and educational reference only. Not medical advice.